AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAR 3 - (NewsRx.com & NewsRx.net) -- Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity.
"Genome-derived neisserial antigen 2132 (GNA2132) is a novel vaccine candidate that was identified during the Neisseria meningitidis group B strain MC58 genome-sequencing project. To assess the vaccine potential of GNA2132, we prepared antisera from mice immunized with recombinant GNA2132 (gene from strain NZ394/98). Anti-GNA2132 antibody bound to the surface of live bacteria from all seven capsular group B or C strains tested and elicited deposition of human Ob on the bacterial surface," researchers in the United States report.
"However, with human or infant-rat Complement, anti-GNA2132 had no detectable bactericidal activity (titer,
Welsch and her coauthors published their study in the Journal of Infectious Diseases (Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis, 2003;188(11):1730-1740).
For additional information, ...